Cargando…

Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study

INTRODUCTION: The primary outcome of the study was to evaluate the effect on 30 day mortality of the combination ceftazidime/avibactam + fosfomycin in the treatment of bloodstream infections (BSIs) caused by KPC-producing Klebsiella pneumoniae (KPC-Kp). MATERIALS AND METHODS: From October 2018 to Ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oliva, A, Volpicelli, L, Di Bari, S, Curtolo, A, Borrazzo, C, Cogliati Dezza, F, Cona, A, Agrenzano, S, Mularoni, A, Trancassini, M, Mengoni, F, Stefani, S, Raponi, G, Venditti, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728520/ https://www.ncbi.nlm.nih.gov/pubmed/36506890 http://dx.doi.org/10.1093/jacamr/dlac121

Ejemplares similares

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K. pneumoniae Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside
por: Oliva, Alessandra, et al.
Publicado: (2021)

Cost-Effectiveness of Short Course of Ceftazidime/Avibactam for K. pneumoniae-KPC Bloodstream Infections in Italy
por: De Benedetto, Ilaria, et al.
Publicado: (2023)

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment
por: Wang, Lin, et al.
Publicado: (2022)

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
por: Huang, Yanqin, et al.
Publicado: (2021)

Correction: Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case–control study
por: Oliva, A., et al.
Publicado: (2022)

Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case–control study
por: Oliva, A., et al.
Publicado: (2022)

Neonatal Bloodstream Infection with Ceftazidime-Avibactam-Resistant bla(KPC-2)-Producing Klebsiella pneumoniae Carrying bla(VEB-25)
por: Zarras, Charalampos, et al.
Publicado: (2023)

Are Follow-Up Blood Cultures Useful in the Antimicrobial Management of Gram Negative Bacteremia? A Reappraisal of Their Role Based on Current Knowledge
por: Cogliati Dezza, Francesco, et al.
Publicado: (2020)

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China
por: Cui, Xiaoyan, et al.
Publicado: (2020)

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
por: Papp-Wallace, Krisztina M., et al.
Publicado: (2023)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)

2160. Emergence of INDEL Mutations in KPC-2: Insights into Ceftazidime-Avibactam and Imipenem-Relebactam Efficacy
por: Brunetti, Florencia, et al.
Publicado: (2023)

Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam
por: Tsivkovski, Ruslan, et al.
Publicado: (2020)

Identification of L169P mutation in the omega loop of KPC-3 after a short course of ceftazidime/avibactam
por: Venditti, Carolina, et al.
Publicado: (2019)

2385. Ceftazidime–Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa
por: Papp-Wallace, Krisztina M, et al.
Publicado: (2018)

Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae
por: Guo, Yingyi, et al.
Publicado: (2021)

1285. Identification of KPC Omega Loop Variant R163S Conferring Ceftazidime-Avibactam Resistance
por: Maris, Alexander S, et al.
Publicado: (2021)

Clinical Impact of COVID-19 on Multi-Drug-Resistant Gram-Negative Bacilli Bloodstream Infections in an Intensive Care Unit Setting: Two Pandemics Compared
por: Cogliati Dezza, Francesco, et al.
Publicado: (2022)

Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in bla(KPC-3)-harboring Klebsiella pneumoniae
por: Venditti, Carolina, et al.
Publicado: (2019)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
por: Yu, Wei, et al.
Publicado: (2021)

Phenotypic and Genetic Analysis of KPC-49, a KPC-2 Variant Conferring Resistance to Ceftazidime–Avibactam and Maintaining Resistance to Imipenem and Meropenem
por: Yu, Meng, et al.
Publicado: (2023)

Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient
por: Vargas, Maria, et al.
Publicado: (2019)

Isolation of a Ceftazidime-Avibactam-Resistant bla(KPC-71)-Positive Klebsiella pneumoniae Clinical Isolate
por: Shen, Siquan, et al.
Publicado: (2022)

Ceftazidime–Avibactam in Combination with Imipenem as Salvage Therapy for ST11 KPC-33-Producing Klebsiella pneumoniae
por: Ding, Li, et al.
Publicado: (2022)

Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam
por: Shen, Siquan, et al.
Publicado: (2022)

The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae
por: Zhang, Ping, et al.
Publicado: (2023)

Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study
por: Campogiani, Laura, et al.
Publicado: (2023)

Multiplicity of bla(KPC) Genes and pKpQIL Plasmid Plasticity in the Development of Ceftazidime-Avibactam and Meropenem Coresistance in Klebsiella pneumoniae Sequence Type 307
por: Arcari, Gabriele, et al.
Publicado: (2023)

Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and related mortality in critically ill patients with CRAB colonization
por: Cogliati Dezza, Francesco, et al.
Publicado: (2023)

Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury: A case report
por: Gugliandolo, Agnese, et al.
Publicado: (2017)

Characterization of KPC-82, a KPC-2 Variant Conferring Resistance to Ceftazidime-Avibactam in a Carbapenem-Nonsusceptible Clinical Isolate of Citrobacter koseri
por: Lebreton, Francois, et al.
Publicado: (2021)

Emergence of KPC-134, a KPC-2 variant associated with ceftazidime-avibactam resistance in a ST11 Klebsiella pneumoniae clinical strain
por: Huang, Xiangning, et al.
Publicado: (2023)

Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam
por: Yasmin, Mohamad, et al.
Publicado: (2020)

Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae Carbapenemase–Producing Klebsiella pneumoniae Infections: A Retrospective, Observational, 2-Center Clinical Study
por: Oliva, Alessandra, et al.
Publicado: (2023)

Ceftazidime/avibactam for specified infections
Publicado: (2020)

Multiple Novel Ceftazidime-Avibactam-Resistant Variants of bla(KPC-2)-Positive Klebsiella pneumoniae in Two Patients
por: Shi, Qingyu, et al.
Publicado: (2022)

Diversity of Ceftazidime-Avibactam Resistance Mechanism in KPC2-Producing Klebsiella pneumoniae Under Antibiotic Selection Pressure
por: Jiang, Min, et al.
Publicado: (2022)

Dynamic evolution of ceftazidime–avibactam resistance due to interchanges between bla(KPC-2) and bla(KPC-145) during treatment of Klebsiella pneumoniae infection
por: Chen, Yili, et al.
Publicado: (2023)

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ifg6b8g0j8jh6bp84mc26lvudf